1. Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. PB Perkeni. 2021.
2. Sapra A, Bhandari P. Diabetes. StatPearls Publishing. 2023.
3. World Health Organization. Diabetes Overview. 2024. https://www.who.int/health-topics/diabetes.
4. Khan M, Hashim M, King J, Govender R, Mustafa H, Kaabi J. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar; 10(1): 107–111.
5. American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes. Diabetes Care 2024;47
6. Eyth E, Naik R. Hemoglobin A1C. StatPearls Publishing. 2023.
7. Sartika F, Hestiani N. Kadar HbA1c pada Pasien Wanita Penderita Diabetes Mellitus Tipe 2 di RSUD Dr. Doris Sylvanus Palangkaraya. Borneo J Of Med Lab Tech. 2019 Okt; 2(1): 97-101.
8. Rodriguez R, Alanis J, Barrera F, McCoy R. Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes. Curr Diab Rep. 2021 Dec 13; 21(12): 63.
9. ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, et al. Glycemic Targets: Standards of Care in Diabetes 2023. Diabetes Care. 2023 Jan; 46(Suppl 1): S97–S110.
10. Ganesan K, Rana M, Sultan S. Oral Hypoglycemic Medications. StatPearls Publishing. 2023 May.
11. Hirukawa H, Hashiramoto M, Tanizawa Y, Kaku K. Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes. J Diabetes Investig. 2018; 9: 1119–1127.
12. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020;43(Supplement_1):S98–S110.
13. Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E. Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. J Clin Med. 2023.
14. Wang GS, et al. Review of Biguanide (Metformin) Toxicity. J Intensive Care Med. 2019;34:863–876.
15. Sola D, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840–848.
16. Dixit J, Badgujar S, Giri P. Reduction in HbA1c through lifestyle modification in newly diagnosed type 2 diabetes mellitus patient: A great feat. J of Fam Med and Prim Care. 2022 June; 11(6): 3312-3317.
17. Jianping Weng. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c >9. J Diabetes. 2017 Oct;9(10):890-893.
18. Yang X, Liu C, He Z, Yuan L, Huang W, Li D, et al. Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel group, randomized, controlled, open-label trial. BMC Endocrine Disorders. 2023 23:215.
19. Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021;44:2438–2444.